Brainstorm Cell Therapeutics Inc. has entered into a Securities Purchase Agreement with an accredited investor for a private placement of its common stock and pre-funded warrants, totaling $1 million in gross proceeds. The transaction will occur in two closings, each for $500,000, with the first closing completed on February 9, 2026, and the second scheduled for 30 days later. Shares are priced at $0.60 each, while pre-funded warrants are priced at $0.5995 with an exercise price of $0.00005 per share. Investors will also receive common stock purchase warrants exercisable for 120% of the shares and pre-funded warrants purchased, with an exercise price of $1.00 per share. The company intends to use the net proceeds for working capital and has agreed to file a registration statement to register the resale of the securities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-015262), on February 13, 2026, and is solely responsible for the information contained therein.
Comments